SlideShare a Scribd company logo
1 of 2
Download to read offline
EpiCast Report: Allergic Rhinitis - Epidemiology Forecast to 2023
Allergic rhinitis is a chronic respiratory disease characterized by inflammation of the nasal cavity and affects people of all ages. The main symptoms of allergic
rhinitis are sneezing, nasal itching, blocked or runny nose and sore throat. Research suggests that a combination of genetic factors such as family history of
allergic rhinitis and environmental factors such as exposure to allergens, including smoke, dust, pollen, insects, molds, or animal dander, may increase the risk for
developing allergic rhinitis. According to the World Health Organization, an estimated 400 million people worldwide were affected with allergic rhinitis during
1996-2006.
According to GlobalData's epidemiological forecast, the total prevalent cases of allergic rhinitis in the 7MM will increase from 123,273,876 total prevalent cases
in 2013 to 125,427,387 total prevalent cases in 2023, at an annual growth rate (AGR) of 0.17% during the forecast period. In 2023, the US will have the highest
number of the total prevalent cases of allergic rhinitis with 39,031,365 total prevalent cases, followed by Japan with 36,602,227 total prevalent cases.
To forecast the total prevalent cases of allergic rhinitis in the 7MM, GlobalData epidemiologists selected nationally representative studies that provided total
prevalence of allergic rhinitis using uniform diagnostic criteria based on the self-reported prevalence of allergic rhinitis. The use of studies that provided uniform
diagnostic criteria for total prevalence of allergic rhinitis facilitated meaningful comparison of the forecast total prevalent cases of allergic rhinitis across the
7MM. Additionally, GlobalData epidemiologists provide the total prevalent cases of allergic rhinitis segmented by the etiological type of allergic rhinitis
(seasonal, perennial, and both), as well as by the severity of allergic rhinitis (mild, moderate, and severe) in these markets. In addition, GlobalData
epidemiologists provide the population of allergic rhinitis cases segmented by sensitization to specific allergens in the six major markets (6MM) (France,
Germany, Italy, Spain, UK and Japan), which are of utmost importance in the management of the condition.
Scope
The Allergic Rhinitis EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends of allergic rhinitis in the 7MM
(US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the total prevalent cases of allergic rhinitis segmented by
sex and age (ages =18 years). The allergic rhinitis epidemiology report is written and developed by Mastersand PhD-level epidemiologists. The EpiCast Report is
in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
Reasons to buy
Develop business strategies by understanding the trends shaping and driving the global allergic rhinitis market. Quantify patient populations in the global
allergic rhinitis market to improve product design, pricing, and launch plans. Organize sales and marketing efforts by identifying the sex and age groups that
present the best opportunities for allergic rhinitis therapeutics in each of the markets covered.
table Of Contents
1 Table Of Contents 4
1.1 List Of Tables 6
1.2 List Of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Upcoming Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors And Comorbidities 10
3.2.1 Family History Of Allergic Rhinitis Is A Strong Predictor For Allergic Rhinitis In Children And Adults 11
3.2.2 Exposure To Allergens In The Environment Increases The Risk For Allergic Rhinitis 12
3.2.3 Urban Living Elevates The Risk Of Allergic Rhinitis 13
3.2.4 People With Allergic Rhinitis Suffer From Several Comorbidities 13
3.3 Global And Historical Trends 15
3.3.1 Us 15
3.3.2 5eu 16
3.3.3 Japan 17
3.4 Forecast Methodology 18
3.4.1 Sources Used 20
3.4.2 Sources Not Used 23
3.4.3 Forecast Assumptions And Methods 24
3.5 Epidemiological Forecast Of Allergic Rhinitis (2013-2023) 28
3.5.1 Total Prevalent Cases Of Allergic Rhinitis 28
3.5.2 Age-specific Total Prevalent Cases Of Allergic Rhinitis 29
3.5.3 Sex-specific Total Prevalent Cases Of Allergic Rhinitis 31
3.5.4 Age-standardized Total Prevalence Of Allergic Rhinitis 33
3.5.5 Distribution Of Total Prevalent Cases Of Allergic Rhinitis By Severity 34
3.5.6 Distribution Of Total Prevalent Cases Of Allergic Rhinitis By Type 35
3.5.7 Allergic Rhinitis Total Prevalent Cases Sensitized To Specific Allergens 36
3.6 Discussion 37
3.6.1 Epidemiological Forecast Insight 37
EpiCast Report: Allergic Rhinitis - Epidemiology Forecast to 2023
3.6.2 Limitations Of The Analysis 38
3.6.3 Strengths Of The Analysis 39
4 Appendix 40
4.1 Bibliography 40
4.2 About The Authors 44
4.2.1 Epidemiologists 44
4.2.2 Reviewers 44
4.2.3 Global Director Of Epidemiology And Health Policy 46
4.2.4 Global Head Of Healthcare 46
4.3 About Globaldata 47
4.4 About Epicast 47
4.5 Disclaimer 48
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
EpiCast Report: Allergic Rhinitis - Epidemiology Forecast to 2023

More Related Content

More from Ambikabasa

Raynauds disease pipeline review, h1 2015
Raynauds disease   pipeline review, h1 2015Raynauds disease   pipeline review, h1 2015
Raynauds disease pipeline review, h1 2015Ambikabasa
 
Travelers diarrhea pipeline review, h1 2015
Travelers diarrhea   pipeline review, h1 2015Travelers diarrhea   pipeline review, h1 2015
Travelers diarrhea pipeline review, h1 2015Ambikabasa
 
Herpes zoster (shingles) pipeline review, h1 2015
Herpes zoster (shingles)   pipeline review, h1 2015Herpes zoster (shingles)   pipeline review, h1 2015
Herpes zoster (shingles) pipeline review, h1 2015Ambikabasa
 
Emphysema pipeline review, h1 2015
Emphysema   pipeline review, h1 2015Emphysema   pipeline review, h1 2015
Emphysema pipeline review, h1 2015Ambikabasa
 
Cerebral infarction (brain infarction) pipeline review, h1 2015
Cerebral infarction (brain infarction)   pipeline review, h1 2015Cerebral infarction (brain infarction)   pipeline review, h1 2015
Cerebral infarction (brain infarction) pipeline review, h1 2015Ambikabasa
 
Seborrhea pipeline review, h1 2015
Seborrhea   pipeline review, h1 2015Seborrhea   pipeline review, h1 2015
Seborrhea pipeline review, h1 2015Ambikabasa
 
Respiratory depression pipeline review, h1 2015
Respiratory depression   pipeline review, h1 2015Respiratory depression   pipeline review, h1 2015
Respiratory depression pipeline review, h1 2015Ambikabasa
 
H1 n1 infection pipeline review, h1 2015
H1 n1 infection   pipeline review, h1 2015H1 n1 infection   pipeline review, h1 2015
H1 n1 infection pipeline review, h1 2015Ambikabasa
 
Nicotine addiction pipeline review, h1 2015
Nicotine addiction   pipeline review, h1 2015Nicotine addiction   pipeline review, h1 2015
Nicotine addiction pipeline review, h1 2015Ambikabasa
 
Food allergy pipeline review, h1 2015
Food allergy   pipeline review, h1 2015Food allergy   pipeline review, h1 2015
Food allergy pipeline review, h1 2015Ambikabasa
 
Uveal melanoma pipeline review, h1 2015
Uveal melanoma   pipeline review, h1 2015Uveal melanoma   pipeline review, h1 2015
Uveal melanoma pipeline review, h1 2015Ambikabasa
 
Tillotts pharma ag product pipeline review - 2015
Tillotts pharma ag   product pipeline review - 2015Tillotts pharma ag   product pipeline review - 2015
Tillotts pharma ag product pipeline review - 2015Ambikabasa
 
Co mentis, inc. product pipeline review - 2015
Co mentis, inc.   product pipeline review - 2015Co mentis, inc.   product pipeline review - 2015
Co mentis, inc. product pipeline review - 2015Ambikabasa
 
Therapure biopharma inc. product pipeline review - 2015
Therapure biopharma inc.   product pipeline review - 2015Therapure biopharma inc.   product pipeline review - 2015
Therapure biopharma inc. product pipeline review - 2015Ambikabasa
 
Genzyme corporation product pipeline review - 2015
Genzyme corporation   product pipeline review - 2015Genzyme corporation   product pipeline review - 2015
Genzyme corporation product pipeline review - 2015Ambikabasa
 
Quantum genomics sa product pipeline review - 2015
Quantum genomics sa   product pipeline review - 2015Quantum genomics sa   product pipeline review - 2015
Quantum genomics sa product pipeline review - 2015Ambikabasa
 
Brain cancer pipeline review, h1 2015
Brain cancer   pipeline review, h1 2015Brain cancer   pipeline review, h1 2015
Brain cancer pipeline review, h1 2015Ambikabasa
 
Diarrhea pipeline review, h1 2015
Diarrhea   pipeline review, h1 2015Diarrhea   pipeline review, h1 2015
Diarrhea pipeline review, h1 2015Ambikabasa
 
Integra gen s.a (alint) product pipeline analysis, 2014 update
Integra gen s.a (alint)   product pipeline analysis, 2014 updateIntegra gen s.a (alint)   product pipeline analysis, 2014 update
Integra gen s.a (alint) product pipeline analysis, 2014 updateAmbikabasa
 
Exercise trends - us - october 2014
Exercise trends  - us - october 2014Exercise trends  - us - october 2014
Exercise trends - us - october 2014Ambikabasa
 

More from Ambikabasa (20)

Raynauds disease pipeline review, h1 2015
Raynauds disease   pipeline review, h1 2015Raynauds disease   pipeline review, h1 2015
Raynauds disease pipeline review, h1 2015
 
Travelers diarrhea pipeline review, h1 2015
Travelers diarrhea   pipeline review, h1 2015Travelers diarrhea   pipeline review, h1 2015
Travelers diarrhea pipeline review, h1 2015
 
Herpes zoster (shingles) pipeline review, h1 2015
Herpes zoster (shingles)   pipeline review, h1 2015Herpes zoster (shingles)   pipeline review, h1 2015
Herpes zoster (shingles) pipeline review, h1 2015
 
Emphysema pipeline review, h1 2015
Emphysema   pipeline review, h1 2015Emphysema   pipeline review, h1 2015
Emphysema pipeline review, h1 2015
 
Cerebral infarction (brain infarction) pipeline review, h1 2015
Cerebral infarction (brain infarction)   pipeline review, h1 2015Cerebral infarction (brain infarction)   pipeline review, h1 2015
Cerebral infarction (brain infarction) pipeline review, h1 2015
 
Seborrhea pipeline review, h1 2015
Seborrhea   pipeline review, h1 2015Seborrhea   pipeline review, h1 2015
Seborrhea pipeline review, h1 2015
 
Respiratory depression pipeline review, h1 2015
Respiratory depression   pipeline review, h1 2015Respiratory depression   pipeline review, h1 2015
Respiratory depression pipeline review, h1 2015
 
H1 n1 infection pipeline review, h1 2015
H1 n1 infection   pipeline review, h1 2015H1 n1 infection   pipeline review, h1 2015
H1 n1 infection pipeline review, h1 2015
 
Nicotine addiction pipeline review, h1 2015
Nicotine addiction   pipeline review, h1 2015Nicotine addiction   pipeline review, h1 2015
Nicotine addiction pipeline review, h1 2015
 
Food allergy pipeline review, h1 2015
Food allergy   pipeline review, h1 2015Food allergy   pipeline review, h1 2015
Food allergy pipeline review, h1 2015
 
Uveal melanoma pipeline review, h1 2015
Uveal melanoma   pipeline review, h1 2015Uveal melanoma   pipeline review, h1 2015
Uveal melanoma pipeline review, h1 2015
 
Tillotts pharma ag product pipeline review - 2015
Tillotts pharma ag   product pipeline review - 2015Tillotts pharma ag   product pipeline review - 2015
Tillotts pharma ag product pipeline review - 2015
 
Co mentis, inc. product pipeline review - 2015
Co mentis, inc.   product pipeline review - 2015Co mentis, inc.   product pipeline review - 2015
Co mentis, inc. product pipeline review - 2015
 
Therapure biopharma inc. product pipeline review - 2015
Therapure biopharma inc.   product pipeline review - 2015Therapure biopharma inc.   product pipeline review - 2015
Therapure biopharma inc. product pipeline review - 2015
 
Genzyme corporation product pipeline review - 2015
Genzyme corporation   product pipeline review - 2015Genzyme corporation   product pipeline review - 2015
Genzyme corporation product pipeline review - 2015
 
Quantum genomics sa product pipeline review - 2015
Quantum genomics sa   product pipeline review - 2015Quantum genomics sa   product pipeline review - 2015
Quantum genomics sa product pipeline review - 2015
 
Brain cancer pipeline review, h1 2015
Brain cancer   pipeline review, h1 2015Brain cancer   pipeline review, h1 2015
Brain cancer pipeline review, h1 2015
 
Diarrhea pipeline review, h1 2015
Diarrhea   pipeline review, h1 2015Diarrhea   pipeline review, h1 2015
Diarrhea pipeline review, h1 2015
 
Integra gen s.a (alint) product pipeline analysis, 2014 update
Integra gen s.a (alint)   product pipeline analysis, 2014 updateIntegra gen s.a (alint)   product pipeline analysis, 2014 update
Integra gen s.a (alint) product pipeline analysis, 2014 update
 
Exercise trends - us - october 2014
Exercise trends  - us - october 2014Exercise trends  - us - october 2014
Exercise trends - us - october 2014
 

Recently uploaded

BeMetals Investor Presentation_May 3, 2024.pdf
BeMetals Investor Presentation_May 3, 2024.pdfBeMetals Investor Presentation_May 3, 2024.pdf
BeMetals Investor Presentation_May 3, 2024.pdfDerekIwanaka1
 
PHX May 2024 Corporate Presentation Final
PHX May 2024 Corporate Presentation FinalPHX May 2024 Corporate Presentation Final
PHX May 2024 Corporate Presentation FinalPanhandleOilandGas
 
How to Get Started in Social Media for Art League City
How to Get Started in Social Media for Art League CityHow to Get Started in Social Media for Art League City
How to Get Started in Social Media for Art League CityEric T. Tung
 
Putting the SPARK into Virtual Training.pptx
Putting the SPARK into Virtual Training.pptxPutting the SPARK into Virtual Training.pptx
Putting the SPARK into Virtual Training.pptxCynthia Clay
 
Paradip CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDING
Paradip CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDINGParadip CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDING
Paradip CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDINGpr788182
 
Falcon Invoice Discounting: Unlock Your Business Potential
Falcon Invoice Discounting: Unlock Your Business PotentialFalcon Invoice Discounting: Unlock Your Business Potential
Falcon Invoice Discounting: Unlock Your Business PotentialFalcon investment
 
New 2024 Cannabis Edibles Investor Pitch Deck Template
New 2024 Cannabis Edibles Investor Pitch Deck TemplateNew 2024 Cannabis Edibles Investor Pitch Deck Template
New 2024 Cannabis Edibles Investor Pitch Deck TemplateCannaBusinessPlans
 
Marel Q1 2024 Investor Presentation from May 8, 2024
Marel Q1 2024 Investor Presentation from May 8, 2024Marel Q1 2024 Investor Presentation from May 8, 2024
Marel Q1 2024 Investor Presentation from May 8, 2024Marel
 
The Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai Kuwait
The Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai KuwaitThe Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai Kuwait
The Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai Kuwaitdaisycvs
 
Uneak White's Personal Brand Exploration Presentation
Uneak White's Personal Brand Exploration PresentationUneak White's Personal Brand Exploration Presentation
Uneak White's Personal Brand Exploration Presentationuneakwhite
 
Mckinsey foundation level Handbook for Viewing
Mckinsey foundation level Handbook for ViewingMckinsey foundation level Handbook for Viewing
Mckinsey foundation level Handbook for ViewingNauman Safdar
 
Cannabis Legalization World Map: 2024 Updated
Cannabis Legalization World Map: 2024 UpdatedCannabis Legalization World Map: 2024 Updated
Cannabis Legalization World Map: 2024 UpdatedCannaBusinessPlans
 
CROSS CULTURAL NEGOTIATION BY PANMISEM NS
CROSS CULTURAL NEGOTIATION BY PANMISEM NSCROSS CULTURAL NEGOTIATION BY PANMISEM NS
CROSS CULTURAL NEGOTIATION BY PANMISEM NSpanmisemningshen123
 
Power point presentation on enterprise performance management
Power point presentation on enterprise performance managementPower point presentation on enterprise performance management
Power point presentation on enterprise performance managementVaishnaviGunji
 
Katrina Personal Brand Project and portfolio 1
Katrina Personal Brand Project and portfolio 1Katrina Personal Brand Project and portfolio 1
Katrina Personal Brand Project and portfolio 1kcpayne
 
Structuring and Writing DRL Mckinsey (1).pdf
Structuring and Writing DRL Mckinsey (1).pdfStructuring and Writing DRL Mckinsey (1).pdf
Structuring and Writing DRL Mckinsey (1).pdflaloo_007
 
Al Mizhar Dubai Escorts +971561403006 Escorts Service In Al Mizhar
Al Mizhar Dubai Escorts +971561403006 Escorts Service In Al MizharAl Mizhar Dubai Escorts +971561403006 Escorts Service In Al Mizhar
Al Mizhar Dubai Escorts +971561403006 Escorts Service In Al Mizharallensay1
 
Getting Real with AI - Columbus DAW - May 2024 - Nick Woo from AlignAI
Getting Real with AI - Columbus DAW - May 2024 - Nick Woo from AlignAIGetting Real with AI - Columbus DAW - May 2024 - Nick Woo from AlignAI
Getting Real with AI - Columbus DAW - May 2024 - Nick Woo from AlignAITim Wilson
 
Arti Languages Pre Seed Teaser Deck 2024.pdf
Arti Languages Pre Seed Teaser Deck 2024.pdfArti Languages Pre Seed Teaser Deck 2024.pdf
Arti Languages Pre Seed Teaser Deck 2024.pdfwill854175
 

Recently uploaded (20)

BeMetals Investor Presentation_May 3, 2024.pdf
BeMetals Investor Presentation_May 3, 2024.pdfBeMetals Investor Presentation_May 3, 2024.pdf
BeMetals Investor Presentation_May 3, 2024.pdf
 
PHX May 2024 Corporate Presentation Final
PHX May 2024 Corporate Presentation FinalPHX May 2024 Corporate Presentation Final
PHX May 2024 Corporate Presentation Final
 
How to Get Started in Social Media for Art League City
How to Get Started in Social Media for Art League CityHow to Get Started in Social Media for Art League City
How to Get Started in Social Media for Art League City
 
Putting the SPARK into Virtual Training.pptx
Putting the SPARK into Virtual Training.pptxPutting the SPARK into Virtual Training.pptx
Putting the SPARK into Virtual Training.pptx
 
Paradip CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDING
Paradip CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDINGParadip CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDING
Paradip CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDING
 
Falcon Invoice Discounting: Unlock Your Business Potential
Falcon Invoice Discounting: Unlock Your Business PotentialFalcon Invoice Discounting: Unlock Your Business Potential
Falcon Invoice Discounting: Unlock Your Business Potential
 
New 2024 Cannabis Edibles Investor Pitch Deck Template
New 2024 Cannabis Edibles Investor Pitch Deck TemplateNew 2024 Cannabis Edibles Investor Pitch Deck Template
New 2024 Cannabis Edibles Investor Pitch Deck Template
 
Marel Q1 2024 Investor Presentation from May 8, 2024
Marel Q1 2024 Investor Presentation from May 8, 2024Marel Q1 2024 Investor Presentation from May 8, 2024
Marel Q1 2024 Investor Presentation from May 8, 2024
 
The Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai Kuwait
The Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai KuwaitThe Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai Kuwait
The Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai Kuwait
 
Uneak White's Personal Brand Exploration Presentation
Uneak White's Personal Brand Exploration PresentationUneak White's Personal Brand Exploration Presentation
Uneak White's Personal Brand Exploration Presentation
 
Mckinsey foundation level Handbook for Viewing
Mckinsey foundation level Handbook for ViewingMckinsey foundation level Handbook for Viewing
Mckinsey foundation level Handbook for Viewing
 
Cannabis Legalization World Map: 2024 Updated
Cannabis Legalization World Map: 2024 UpdatedCannabis Legalization World Map: 2024 Updated
Cannabis Legalization World Map: 2024 Updated
 
unwanted pregnancy Kit [+918133066128] Abortion Pills IN Dubai UAE Abudhabi
unwanted pregnancy Kit [+918133066128] Abortion Pills IN Dubai UAE Abudhabiunwanted pregnancy Kit [+918133066128] Abortion Pills IN Dubai UAE Abudhabi
unwanted pregnancy Kit [+918133066128] Abortion Pills IN Dubai UAE Abudhabi
 
CROSS CULTURAL NEGOTIATION BY PANMISEM NS
CROSS CULTURAL NEGOTIATION BY PANMISEM NSCROSS CULTURAL NEGOTIATION BY PANMISEM NS
CROSS CULTURAL NEGOTIATION BY PANMISEM NS
 
Power point presentation on enterprise performance management
Power point presentation on enterprise performance managementPower point presentation on enterprise performance management
Power point presentation on enterprise performance management
 
Katrina Personal Brand Project and portfolio 1
Katrina Personal Brand Project and portfolio 1Katrina Personal Brand Project and portfolio 1
Katrina Personal Brand Project and portfolio 1
 
Structuring and Writing DRL Mckinsey (1).pdf
Structuring and Writing DRL Mckinsey (1).pdfStructuring and Writing DRL Mckinsey (1).pdf
Structuring and Writing DRL Mckinsey (1).pdf
 
Al Mizhar Dubai Escorts +971561403006 Escorts Service In Al Mizhar
Al Mizhar Dubai Escorts +971561403006 Escorts Service In Al MizharAl Mizhar Dubai Escorts +971561403006 Escorts Service In Al Mizhar
Al Mizhar Dubai Escorts +971561403006 Escorts Service In Al Mizhar
 
Getting Real with AI - Columbus DAW - May 2024 - Nick Woo from AlignAI
Getting Real with AI - Columbus DAW - May 2024 - Nick Woo from AlignAIGetting Real with AI - Columbus DAW - May 2024 - Nick Woo from AlignAI
Getting Real with AI - Columbus DAW - May 2024 - Nick Woo from AlignAI
 
Arti Languages Pre Seed Teaser Deck 2024.pdf
Arti Languages Pre Seed Teaser Deck 2024.pdfArti Languages Pre Seed Teaser Deck 2024.pdf
Arti Languages Pre Seed Teaser Deck 2024.pdf
 

Epi cast report allergic rhinitis - epidemiology forecast to 2023

  • 1. EpiCast Report: Allergic Rhinitis - Epidemiology Forecast to 2023 Allergic rhinitis is a chronic respiratory disease characterized by inflammation of the nasal cavity and affects people of all ages. The main symptoms of allergic rhinitis are sneezing, nasal itching, blocked or runny nose and sore throat. Research suggests that a combination of genetic factors such as family history of allergic rhinitis and environmental factors such as exposure to allergens, including smoke, dust, pollen, insects, molds, or animal dander, may increase the risk for developing allergic rhinitis. According to the World Health Organization, an estimated 400 million people worldwide were affected with allergic rhinitis during 1996-2006. According to GlobalData's epidemiological forecast, the total prevalent cases of allergic rhinitis in the 7MM will increase from 123,273,876 total prevalent cases in 2013 to 125,427,387 total prevalent cases in 2023, at an annual growth rate (AGR) of 0.17% during the forecast period. In 2023, the US will have the highest number of the total prevalent cases of allergic rhinitis with 39,031,365 total prevalent cases, followed by Japan with 36,602,227 total prevalent cases. To forecast the total prevalent cases of allergic rhinitis in the 7MM, GlobalData epidemiologists selected nationally representative studies that provided total prevalence of allergic rhinitis using uniform diagnostic criteria based on the self-reported prevalence of allergic rhinitis. The use of studies that provided uniform diagnostic criteria for total prevalence of allergic rhinitis facilitated meaningful comparison of the forecast total prevalent cases of allergic rhinitis across the 7MM. Additionally, GlobalData epidemiologists provide the total prevalent cases of allergic rhinitis segmented by the etiological type of allergic rhinitis (seasonal, perennial, and both), as well as by the severity of allergic rhinitis (mild, moderate, and severe) in these markets. In addition, GlobalData epidemiologists provide the population of allergic rhinitis cases segmented by sensitization to specific allergens in the six major markets (6MM) (France, Germany, Italy, Spain, UK and Japan), which are of utmost importance in the management of the condition. Scope The Allergic Rhinitis EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends of allergic rhinitis in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the total prevalent cases of allergic rhinitis segmented by sex and age (ages =18 years). The allergic rhinitis epidemiology report is written and developed by Mastersand PhD-level epidemiologists. The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM. Reasons to buy Develop business strategies by understanding the trends shaping and driving the global allergic rhinitis market. Quantify patient populations in the global allergic rhinitis market to improve product design, pricing, and launch plans. Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for allergic rhinitis therapeutics in each of the markets covered. table Of Contents 1 Table Of Contents 4 1.1 List Of Tables 6 1.2 List Of Figures 7 2 Introduction 8 2.1 Catalyst 8 2.2 Upcoming Reports 8 3 Epidemiology 9 3.1 Disease Background 9 3.2 Risk Factors And Comorbidities 10 3.2.1 Family History Of Allergic Rhinitis Is A Strong Predictor For Allergic Rhinitis In Children And Adults 11 3.2.2 Exposure To Allergens In The Environment Increases The Risk For Allergic Rhinitis 12 3.2.3 Urban Living Elevates The Risk Of Allergic Rhinitis 13 3.2.4 People With Allergic Rhinitis Suffer From Several Comorbidities 13 3.3 Global And Historical Trends 15 3.3.1 Us 15 3.3.2 5eu 16 3.3.3 Japan 17 3.4 Forecast Methodology 18 3.4.1 Sources Used 20 3.4.2 Sources Not Used 23 3.4.3 Forecast Assumptions And Methods 24 3.5 Epidemiological Forecast Of Allergic Rhinitis (2013-2023) 28 3.5.1 Total Prevalent Cases Of Allergic Rhinitis 28 3.5.2 Age-specific Total Prevalent Cases Of Allergic Rhinitis 29 3.5.3 Sex-specific Total Prevalent Cases Of Allergic Rhinitis 31 3.5.4 Age-standardized Total Prevalence Of Allergic Rhinitis 33 3.5.5 Distribution Of Total Prevalent Cases Of Allergic Rhinitis By Severity 34 3.5.6 Distribution Of Total Prevalent Cases Of Allergic Rhinitis By Type 35 3.5.7 Allergic Rhinitis Total Prevalent Cases Sensitized To Specific Allergens 36 3.6 Discussion 37 3.6.1 Epidemiological Forecast Insight 37 EpiCast Report: Allergic Rhinitis - Epidemiology Forecast to 2023
  • 2. 3.6.2 Limitations Of The Analysis 38 3.6.3 Strengths Of The Analysis 39 4 Appendix 40 4.1 Bibliography 40 4.2 About The Authors 44 4.2.1 Epidemiologists 44 4.2.2 Reviewers 44 4.2.3 Global Director Of Epidemiology And Health Policy 46 4.2.4 Global Head Of Healthcare 46 4.3 About Globaldata 47 4.4 About Epicast 47 4.5 Disclaimer 48 ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ EpiCast Report: Allergic Rhinitis - Epidemiology Forecast to 2023